Journal article

A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [F-18]flutemetamol amyloid PET images

Marco Bucci, Irina Savitcheva, Gill Farrar, Gemma Salvado, Lyduine Collij, Vincent Dore, Juan Domingo Gispert, Roger Gunn, Bernard Hanseeuw, Oskar Hansson, Mahnaz Shekari, Renaud Lhommel, Jose Luis Molinuevo, Christopher Rowe, Cyrille Sur, Alex Whittington, Christopher Buckley, Agneta Nordberg



BACKGROUND: [18F]flutemetamol PET scanning provides information on brain amyloid load and has been approved for routine clinical use based upon visual interpretation as either negative (equating to none or sparse amyloid plaques) or amyloid positive (equating to moderate or frequent plaques). Quantitation is however fundamental to the practice of nuclear medicine and hence can be used to supplement amyloid reading methodology especially in unclear cases. METHODS: A total of 2770 [18F]flutemetamol images were collected from 3 clinical studies and 6 research cohorts with available visual reading of [18F]flutemetamol and quantitative analysis of images. These were assessed further to examine bo..

View full abstract


Awarded by Swedish Foundation for Strategic Research (SSF)

Awarded by la Caixa Foundation

Awarded by TriBEKa Imaging Platform project

Funding Acknowledgements

Swedish Brain Foundation, Swedish Foundation for Strategic Research (SSF) (Project RB13-0192), Stockholm RegionKarolinsa institutet (ALF grant), Center for Innovative Medicine (CIMED) Stockholm Region, Karolinska institutet. Medical Radiation Physics and Nuclear Medicine, Section for Nuclear Medicine, Karolinska University Hospital (Stockholm, Sweden); for the ALFA cohort: la Caixa Foundation (LCF/PR/GN17/50300004) and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17519007). Mark Battle (GEHC), Bart NM van Berckel, Femke Bouwman, Philip Scheltens, Marissa Zwan (for the Dutch Flutemetamol Study), Adrian Ivanoiu (St Luc), The ALFA+ cohort (Barcelona), the AIBL cohort (Melbourne, Australia), the Biofinder cohort (Lund, Sweden).